What MangoRx is selling
MangoRx is a men's health telehealth brand. Its GLP-1 product is a compounded oral semaglutide tablet, sold next to a catalog of testosterone, hair-loss, and erectile dysfunction treatments. The GLP-1 is one line in a broader offering rather than the whole business. A reader comparing dedicated weight-management programs is not comparing like with like here.
The oral tablet is the genuine point of difference. Almost everything else in this comparison is a weekly injection. MangoRx sells a once-daily dissolving tablet. For a reader whose real objection to GLP-1 treatment is the needle rather than the price, that reframes the decision entirely. A daily tablet is also a different adherence problem than a weekly shot — easier to start, easier to forget. Be honest with yourself about which failure mode you are more prone to.
The parent company, and what that actually buys you
MangoRx operates under Mangoceuticals, a company listed on the Nasdaq under MGRX. That is not a marketing detail. A publicly traded parent carries SEC reporting obligations that most privately held telehealth brands do not have. A determined reader can pull filings and read something about the business behind the website rather than guessing at it. In a category full of anonymous LLCs, that is a real and checkable difference.
It is also a narrow one. Public reporting tells you about the company's finances and its disclosures to investors. It tells you nothing about which pharmacy compounds the tablet, what accreditation that pharmacy holds, or whether the service is licensed where you live. Corporate transparency and clinical transparency are separate things, and MangoRx has considerably more of the first than the second.
The 25-day refill, which is the mistake most readers will make
MangoRx's subscribe-and-save cycle refills every twenty-five days rather than monthly. Read that sentence again, because it is the most expensive detail here. A reader who files the published figure as a monthly cost and multiplies by twelve will get the annual cost wrong, in the provider's favor, every time. A twenty-five day cycle produces more fills in a year than a calendar month does.
That is why the figure appears with its actual refill period attached. The number is not wrong. The assumption a reader brings to it is what goes wrong. Anyone comparing MangoRx against a monthly-billed competitor has to normalize both to the same period before the comparison means anything. A table that quietly treats a twenty-five day fill as a month is not telling the truth about the gap.
What MangoRx does not publish
MangoRx does not name the compounding pharmacy that prepares its tablet. It describes licensure in general terms and discloses no third-party pharmacy accreditation beyond that. For a compounded product, the identity of the pharmacy is the single fact a reader would most want to look up, and here it is not available.
MangoRx is also silent on where it can legally ship. It publishes no list of states served. No published list is not the same thing as nationwide availability, and the gap is left as a gap here. A reader outside a major market should establish state availability directly with MangoRx before starting an intake, because nothing on the public record settles it.
Both of these are absences, and they are stated as absences. Nothing MangoRx publishes contradicts them, and nothing fills them in. That is the honest description of the record as it stands.
How to weigh it
There is a version of this reader for whom MangoRx makes sense. Someone already using the platform for testosterone or hair loss, who wants one login and one clinical relationship. Someone who prefers a daily tablet to a weekly injection, and who is willing to call and confirm what the website leaves out. That reader is real, and MangoRx is a reasonable fit for them.
For everyone else, the gaps are hard to argue past. Several providers in this comparison publish a state list, a pharmacy name, or both, and charge on a calendar month. Choosing MangoRx over those means accepting less information for no structural advantage other than the tablet. If the tablet is the reason, it is a defensible trade. If it is not, there is little here to justify it.
MangoRx's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded-oral) | $299/moper fill; ships every 25 days, not monthly | August 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. None of the 16 providers reviewed here are paid partners today. See how this works.
See MangoRx's current price →Good fit if
- Readers whose real objection is the weekly injection — the once-daily dissolving tablet is the product's genuine point of difference.
- Existing MangoRx customers already using the platform for testosterone, hair loss, or ED who want everything under one account.
- Readers who put weight on a publicly traded parent and the SEC filing obligations that come with it.
- Comparison shoppers willing to contact the company directly to confirm the details the site does not publish.
Look elsewhere if
- Anyone who needs to know which pharmacy compounds their medication. MangoRx does not name one, and no amount of reading the site will produce it.
- Readers who need to confirm their state is served before paying. MangoRx publishes no state list, and an absent list is not a nationwide claim — several competitors here publish theirs outright.
- Anyone budgeting on a calendar month. The subscribe-and-save cycle refills every twenty-five days, which produces more fills per year than a reader assuming monthly billing will expect.
- Readers who want a displayed third-party pharmacy accreditation. MangoRx discloses none beyond a general claim of licensure.
How this review was verified
- Read MangoRx's published pricing at its source URL and logged the figure with the date it was read.
- Took the refill period MangoRx states — every twenty-five days, not monthly — and attached it to the price qualifier, so it cannot be separated from the figure in a comparison table.
- Checked the site for the name of the compounding pharmacy. MangoRx names none, and no network description was substituted for one.
- Looked for a published list of states served and found none. That absence is carried as an absence rather than as nationwide coverage.
- Took the parent company and its listing (Mangoceuticals, Nasdaq: MGRX) from the company's own disclosure, and screened the entity behind the brand against the FDA warning letter record, which shows no letter for MangoRx.